SS-31 (Elamipretide): A Comprehensive Guide to Mitochondrial-Targeting Peptide Therapy

SS-31 (Elamipretide): A Comprehensive Guide to Mitochondrial-Targeting Peptide Therapy

Introduction

Mitochondria serve as the powerhouses of our cells, generating the energy required for virtually every biological process in the human body. These remarkable organelles are responsible for producing adenosine triphosphate (ATP), managing reactive oxygen species (ROS), and regulating cellular apoptosis [1]. When mitochondrial function becomes compromised, the consequences can be profound, contributing to a wide spectrum of disorders including cardiovascular disease, neurodegenerative conditions, metabolic syndromes, and the natural aging process itself [2].

The recognition that mitochondrial dysfunction underlies numerous chronic diseases has sparked intense scientific interest in developing therapies that can specifically target and restore mitochondrial health. Among the most promising of these therapeutic approaches is SS-31, also known as Elamipretide, MTP-131, or Bendavia. This synthetic tetrapeptide represents a breakthrough in mitochondria-targeted medicine, offering a novel mechanism for addressing cellular energy deficits, oxidative stress, and the structural deterioration of mitochondria that occurs in disease and aging [3].

Elamipretide has garnered significant attention from the research community, with over 174 citations in peer-reviewed literature and multiple clinical trials investigating its therapeutic potential [3]. In September 2025, the compound achieved a major milestone when the U.S. Food and Drug Administration (FDA) approved it for the treatment of Barth syndrome, a rare genetic mitochondrial disorder [4]. This approval marked the first FDA-authorized therapy specifically designed to target mitochondrial dysfunction through cardiolipin stabilization.

This comprehensive guide explores the structure, mechanism of action, preclinical research findings, clinical trial results, and therapeutic potential of SS-31. We examine how this mitochondria-targeting peptide selectively binds to cardiolipin, a critical phospholipid in the inner mitochondrial membrane, thereby stabilizing mitochondrial structure, reducing oxidative stress, and enhancing ATP production. We also discuss the implications of recent research demonstrating that SS-31 can reverse age-related mitochondrial dysfunction and improve exercise tolerance without increasing mitochondrial content—a finding with profound implications for aging populations [2].

Understanding SS-31: Structure and Design

The Tetrapeptide Sequence

Elamipretide is a synthetic tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH₂ [1]. This carefully engineered structure was designed with specific functional goals: to penetrate cell membranes, accumulate selectively in mitochondria, and interact with cardiolipin to stabilize mitochondrial structure and function [1].

Each component of the tetrapeptide plays a crucial role in its biological activity. The peptide contains two positively charged amino acids—D-arginine (D-Arg) and lysine (Lys)—which enable it to preferentially target the inner mitochondrial membrane. This membrane has a high content of negatively charged cardiolipin, and the electrostatic attraction between the positive charges of SS-31 and the negative charges of cardiolipin facilitates the peptide's accumulation within mitochondria [1].

Unique Structural Features

Despite containing positively charged residues that might typically impair membrane permeability, Elamipretide retains remarkably high cell permeability. This property is attributed to positive charge shielding by electrons in the π orbitals of aromatic rings present in phenylalanine (Phe) and dimethyltyrosine (Dmt) [1]. The Dmt residue serves an additional critical function by preventing oxidation, thereby contributing to the peptide's overall chemical stability [1].

The amphipathic nature of Elamipretide—possessing both hydrophobic regions (Phe and Dmt) and hydrophilic regions (D-Arg and Lys)—allows it to interact effectively with both the lipid bilayer and the aqueous cellular environment. This dual character promotes mitochondrial targeting and facilitates membrane penetration [1].

The combination of hydrophobic interactions through Dmt and Phe, along with electrostatic interactions through D-Arg and Lys, enables Elamipretide to specifically accumulate in mitochondria and bind to cardiolipin. This binding interaction stabilizes mitochondrial membranes and prevents the detachment of proteins critical for maintaining mitochondrial function [1].

Mechanism of Action: How SS-31 Protects Mitochondria

Cardiolipin: The Key Target

To understand how SS-31 works, we must first appreciate the critical role of cardiolipin, a unique phospholipid found almost exclusively in the inner mitochondrial membrane [1]. Cardiolipin plays an essential role in maintaining mitochondrial cristae structure and supporting the function of electron transport chain complexes. Unlike typical phospholipids that contain two fatty acid chains, cardiolipin has a distinctive structure consisting of a glycerol backbone with two phosphate groups and four fatty acid chains [1].

During mitochondrial dysfunction, cardiolipin undergoes oxidation, leading to impaired mitochondrial bioenergetics and ultimately cell death [1]. Cardiolipin abnormalities have been implicated in numerous mitochondria-associated conditions including cardiovascular diseases, neurodegenerative disorders such as Parkinson's and Alzheimer's disease, metabolic disorders including diabetes and obesity, and the aging process itself [1].

SS-31's Interaction with Cardiolipin

Elamipretide localizes to the inner mitochondrial membrane and binds to cardiolipin via electrostatic interactions mediated by its positively charged amino acid residues [1]. This binding stabilizes cardiolipin, preventing oxidative damage and maintaining mitochondrial membrane potential. By reducing cardiolipin peroxidation, SS-31 preserves mitochondrial structure and function through several mechanisms: maintenance of cristae integrity, reduction in ROS production, and preservation of mitochondrial ATP production [1].

Research using advanced protein interaction mapping techniques has revealed that SS-31 interacts with multiple mitochondrial proteins beyond cardiolipin, suggesting a complex network of protective effects [3]. The stabilization of cardiolipin by Elamipretide results in improved mitochondrial function, reduced oxidative stress, and mitigated cell damage—all essential factors contributing to its therapeutic potential in diseases involving mitochondrial dysfunction [1].

Enhancement of Mitochondrial Bioenergetics

Mitochondria produce ATP through oxidative phosphorylation (OXPHOS) via the electron transport chain (ETC). Impaired functioning of the ETC decreases ATP generation, leading to energy deficits particularly in highly energetic tissues like the heart and skeletal muscle [1].

Elamipretide enhances the activity of mitochondrial respiratory complexes (I, III, and IV) by promoting their assembly and stability [1]. This enhancement facilitates more efficient electron transfer and ATP synthesis. By improving electron transport chain function, Elamipretide minimizes electron leakage, which is a significant source of mitochondrial ROS production [1].

Elamipretide also plays a crucial role in restoring the mitochondrial membrane potential (ΔΨm) essential for ATP synthesis. By preventing cardiolipin peroxidation and stabilizing the inner mitochondrial membrane, SS-31 helps maintain ΔΨm, which is critical for ATP production [1].

Reduction of Oxidative Stress

Excess ROS production within mitochondria leads to oxidative damage implicated in the pathogenesis of cardiovascular diseases, ischemia-reperfusion injury, and heart failure [1]. High levels of ROS can damage mitochondrial DNA, proteins, and lipids, leading to impaired mitochondrial function.

Elamipretide reduces ROS production by improving the efficiency of the electron transport chain, thus preventing oxidative stress. By reducing electron leakage—a major source of ROS production in mitochondria—SS-31 helps protect mitochondrial lipids like cardiolipin and mitochondrial proteins from oxidative damage [1].

Inhibition of Mitochondrial Permeability Transition Pore Opening

The mitochondrial permeability transition pore (mPTP) is a channel that opens during cellular stress, such as during ischemia-reperfusion injury. When mPTP opens, it leads to mitochondrial swelling, depolarization, and the release of pro-apoptotic factors, ultimately triggering cell death [1].

Elamipretide reduces oxidative stress and stabilizes cardiolipin, thereby maintaining the mitochondrial membrane potential and inhibiting mPTP opening [1]. By preventing mPTP opening, SS-31 protects against mitochondrial damage during reperfusion and reduces cell death and tissue damage in ischemic conditions [1].

Anti-Apoptotic and Anti-Fibrotic Effects

Mitochondrial dysfunction leads to the activation of apoptotic pathways through the release of cytochrome c and the activation of caspases [1]. Over time, chronic mitochondrial damage and oxidative stress contribute to fibrosis, especially in cardiac tissue.

By preserving mitochondrial function, Elamipretide prevents the release of cytochrome c and the subsequent activation of caspase-dependent apoptotic pathways [1]. This is particularly important in preventing cardiomyocyte death in heart failure and ischemic conditions. Preclinical studies have demonstrated that Elamipretide reduces fibrosis in heart tissue by mitigating mitochondrial dysfunction and oxidative stress, both of which are key drivers of fibroblast activation and extracellular matrix deposition [1].

Key Research Findings

Reversing Age-Related Mitochondrial Dysfunction

One of the most significant research findings regarding SS-31 comes from a landmark study by Campbell and colleagues published in Free Radical Biology and Medicine [2]. This research demonstrated that SS-31 could reverse age-related decline in mitochondrial function and improve exercise tolerance in aged mice.

In this study, young (5 months) and aged (26 months) female mice were treated for 8 weeks with SS-31. The results were remarkable: treatment reversed age-related decline in maximum mitochondrial ATP production and improved coupling of oxidative phosphorylation [2]. Importantly, these improvements occurred without an increase in mitochondrial content—mitochondrial protein expression was either unchanged or reduced in treated aged mice [2].

The study revealed that SS-31 restored redox homeostasis in aged skeletal muscle. The glutathione redox status became more reduced, and proteomic analysis indicated a robust reversal of cysteine S-glutathionylation post-translational modifications across the skeletal muscle proteome [2]. This restoration of redox balance translated into functional improvements: the gastrocnemius muscle in treated aged mice was more fatigue-resistant with significantly greater mass compared to aged controls, contributing to a significant increase in treadmill endurance [2].

These results demonstrate that the shift in redox homeostasis due to mitochondrial oxidant production in aged muscle is a key factor in energetic defects and exercise intolerance. Critically, the study showed that SS-31 improves mitochondrial quality rather than quantity—a finding with profound implications for therapeutic approaches to aging and age-related functional decline [2].

Cardiovascular Research

Preclinical studies in animal models of heart failure have demonstrated that Elamipretide can improve cardiac function and prevent progressive left ventricular enlargement [1]. In dogs with advanced heart failure, chronic therapy with SS-31 improved left ventricular function, with significant increases in ejection fraction, stroke volume, cardiac output, and cardiac index, along with decreased left ventricular end-diastolic pressure and systemic vascular resistance [1].

These improvements in cardiac function were accompanied by normalization of heart failure biomarkers (natriuretic peptides and proinflammatory cytokines) and reversal of mitochondrial dysfunction, evidenced by improved ATP synthesis and reduced ROS formation [1]. Dogs treated with Elamipretide also displayed reduced cardiomyocyte hypertrophy and interstitial fibrosis, as well as increased capillary density, indicating beneficial effects on left ventricular remodeling [1].

Kidney Disease Applications

Elamipretide has shown promise in renal disease models, particularly in mitigating damage from ischemia-reperfusion injury and diabetic nephropathy [5]. In mouse models of ischemia-reperfusion injury, administration of SS-31 led to a reduction in kidney injury, demonstrated by improved mitochondrial integrity and decreased oxidative stress [5].

In murine models of diabetic nephropathy, a condition characterized by mitochondrial damage due to chronic hyperglycemia, Elamipretide protected mitochondrial structure and restored mitochondrial function in renal cells, helping to reduce oxidative damage and fibrosis in kidney tissue [5].

Neuroprotective Potential

Mitochondrial dysfunction and oxidative stress have been implicated in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. In Alzheimer's disease, the accumulation of amyloid-beta (Aβ) within neural mitochondria impairs the mitochondrial electron transport chain, leading to ATP reduction [1].

Studies utilizing mouse models of Alzheimer's disease found that Elamipretide therapy recovered mitochondrial function and increased neurite outgrowth, indicating protection against Aβ toxicity [1]. Separate research demonstrated that Elamipretide upregulated neural mitochondrial biogenesis against Aβ aggregation [1].

Elamipretide was also evaluated in mouse models of Parkinson's disease and produced dose-dependent protection of dopaminergic neurons from oxidative damage and mitochondrial dysfunction, suggesting potential for slowing the progression of neurodegeneration [1].

Clinical Trials: From Bench to Bedside

TAZPOWER Trial: FDA Approval for Barth Syndrome

The most successful clinical application of Elamipretide to date has been in Barth syndrome, a rare X-linked genetic disorder caused by defects in the Tafazzin (TAZ) enzyme involved in cardiolipin remodeling [1]. Barth syndrome clinically presents with cardiac left ventricular noncompaction, early-onset cardiomyopathy, intermittent neutropenia, abnormal growth, and skeletal myopathy. The abnormal cardiolipin content resulting from TAZ deficiency culminates in severe mitochondrial deficiency [1].

The TAZPOWER trial was a Phase 2/3 randomized, double-blind, placebo-controlled crossover study that found daily administration of Elamipretide for 48 weeks significantly improved symptoms of Barth syndrome, including augmentation of skeletal muscle strength and cardiac stroke volume [1]. A subsequent 168-week open-label extension study demonstrated sustained long-term tolerability and efficacy, with significant improvements in the six-minute walk test (6MWT), reduced total fatigue scores, and improvements in cardiac parameters including stroke volume, left ventricular end-diastolic volume, and left ventricular end-systolic volume [1].

Based on these compelling results, the FDA approved Elamipretide for the treatment of Barth syndrome in September 2025 [4], marking a historic milestone as the first FDA-approved therapy specifically targeting mitochondrial dysfunction through cardiolipin stabilization.

PROGRESS-HF Trial: Heart Failure with Reduced Ejection Fraction

The PROGRESS-HF trial was a randomized, double-blind, placebo-controlled Phase 2 study that enrolled patients with stable heart failure with reduced ejection fraction (HFrEF) at 20 centers in Europe [1]. While improvements were observed in mitochondrial function and quality of life, the primary endpoint—a reduction in left ventricular end-systolic volume—was not achieved [1].

Several hypotheses have been proposed to explain these results. The four-week treatment duration tested in PROGRESS-HF may have been insufficient, as animal model studies used three-month therapy durations [1]. Additionally, the mitochondrial function improvement offered by Elamipretide may be less apparent in patients already receiving contemporary guideline-directed medical therapy, or effects may be more evident during times of higher energetic demand such as during exercise [1].

Despite not meeting primary endpoints, trending improvements in quality of life scores with Elamipretide suggest promising areas for further investigation, especially given preclinical studies demonstrating improvements in skeletal muscle function and exercise tolerance in heart failure models [1].

ReCLAIM Trial: Age-Related Macular Degeneration

The ReCLAIM study was a randomized, double-blind, placebo-controlled, multicenter Phase 2 trial evaluating the effects of Elamipretide in patients over 55 years of age with dry age-related macular degeneration (AMD) [1]. AMD is the leading cause of irreversible blindness in people aged over 50 years, primarily caused by photoreceptor dysfunction.

While primary endpoints of changes in low luminance best-corrected visual acuity and geographic atrophy area were not observed, Elamipretide was associated with a slowing of progressive ellipsoid zone (EZ) degradation [1]. The EZ is thought to correspond to the mitochondria-rich layer of the photoreceptors, and EZ degradation is a predictor for progressive pathological changes associated with vision loss in AMD. The reduction in EZ degradation may correlate with reduced progressive photoreceptor degeneration, confirming the potential of Elamipretide to preserve photoreceptor function and slow the progression of vision loss in dry AMD [1].

MMPOWER-3 Trial: Primary Mitochondrial Myopathies

Primary mitochondrial myopathies (PMM) are a group of genetic disorders characterized by impaired mitochondrial oxidative phosphorylation leading to muscle weakness and fatigue. The MMPOWER-3 trial was a randomized, double-blind, placebo-controlled Phase 3 study that evaluated the safety and efficacy of Elamipretide in patients with genetically confirmed PMM [1].

While the study did not meet its primary endpoint of improvements in the six-minute walk test overall, participants treated with Elamipretide reported slightly less total fatigue [1]. Importantly, improvement in 6MWT outcomes was observed in a subgroup of participants with nuclear DNA (nDNA) defects [1]. Recent post hoc analyses revealed beneficial effects of Elamipretide in PMM patients with replisome disorders of mitochondrial DNA (mtDNA), highlighting the importance of accounting for specific genetic subtypes in PMM clinical trials [1]. These findings formed the basis for a follow-up Phase 3 clinical trial (NuPOWER) aimed at evaluating the efficacy of Elamipretide in patients with mtDNA maintenance-related disorders.

EMBRACE-STEMI Trial: Acute Myocardial Infarction

The EMBRACE-STEMI clinical trial was a multicenter, randomized, double-blind Phase 2a study that evaluated the efficacy and safety of Elamipretide among first-time anterior ST-elevation myocardial infarction (STEMI) patients who received primary percutaneous coronary intervention [1].

The results showed that Elamipretide was not associated with a decrease in myocardial infarct size. However, the reduced incidence of heart failure within 24 hours following PCI—which comprised approximately 75% of all new-onset heart failure events—was associated with Elamipretide treatment, although the incidence of heart failure after 24 hours was not reduced [1].

Safety Profile and Tolerability

Multiple clinical trials have demonstrated a favorable tolerability profile for Elamipretide [1]. Reported side effects have been mild and transient, with the most common event being injection site reactions, including pain at the injection site, redness, and swelling. Other less common adverse events include mild to moderate headaches, dizziness, nausea, abdominal pain, and fatigue during treatment [1].

Reports of more severe side effects include rare instances of urticaria [1]. Clinical trials noted no clinically significant differences in vital signs, laboratory values, physical examination findings, and ECG-measured parameters, even in the 168-week open-label extension of the TAZPOWER trial [1].

Overall, Elamipretide has been shown to be generally well-tolerated, leading to the conclusion that the benefits of Elamipretide outweigh the risks for patients with mitochondrial dysfunction-related conditions [1]. Continued research and monitoring will provide further insights into the long-term safety and tolerability of Elamipretide as its clinical use expands.

Research Applications and Future Directions

Aging and Sarcopenia

The demonstration that SS-31 can reverse age-related mitochondrial dysfunction and improve exercise tolerance without increasing mitochondrial content represents a paradigm shift in our understanding of aging interventions [2]. Sarcopenia (age-related muscle loss) and exercise intolerance are major contributors to reduced quality of life in the elderly, for which there are few effective treatments.

The finding that SS-31 improves mitochondrial quality rather than quantity suggests that therapeutic approaches focused on optimizing existing mitochondrial function may be more effective than strategies aimed at increasing mitochondrial biogenesis [2]. Since Elamipretide is currently in clinical trials for various conditions, these preclinical results indicate it may have direct translational value for improving exercise tolerance and quality of life in elderly populations.

Metabolic Disorders

Research has explored the potential of SS-31 in metabolic disorders characterized by mitochondrial dysfunction, including diabetes and obesity [1]. Altered cardiolipin profiles have been observed in metabolic disorders where energy metabolism and mitochondrial function are affected. The ability of Elamipretide to stabilize cardiolipin and improve mitochondrial bioenergetics suggests potential applications in addressing metabolic dysfunction.

Ischemia-Reperfusion Injury

Preclinical studies have demonstrated the protective effects of SS-31 in ischemia-reperfusion injury across multiple organ systems [1]. By inhibiting mPTP opening and reducing oxidative stress, Elamipretide protects against mitochondrial damage during reperfusion, reducing cell death and tissue damage. A Phase 2a trial in patients with atherosclerotic renal artery stenosis found that adjunctive Elamipretide before and during stent revascularization attenuated postprocedural hypoxia, increased renal blood flow, and improved kidney function when measured three months later [1].

Chemotherapy-Induced Cardiotoxicity

Doxorubicin, a commonly used chemotherapeutic agent, causes dose-dependent cardiotoxicity primarily mediated through the generation of excess ROS in mitochondria, leading to oxidative damage of mitochondrial DNA, lipids (particularly cardiolipin), and proteins [1]. The cardiolipin-targeting mechanism makes Elamipretide particularly effective at addressing mitochondrial damage induced by doxorubicin, and several preclinical studies have demonstrated its potential to mitigate doxorubicin-induced cardiotoxicity [1].

Comparison with Other Mitochondrial Therapies

SS-31 distinguishes itself through its unique mechanism of directly stabilizing cardiolipin and its demonstrated ability to improve mitochondrial quality without requiring increased mitochondrial content [2]. This represents a fundamentally different approach compared to interventions that primarily aim to increase mitochondrial biogenesis or provide general antioxidant effects.

Conclusion

Elamipretide (SS-31) represents a breakthrough in mitochondria-targeted therapeutics, offering a novel mechanism of intervention in diseases characterized by mitochondrial dysfunction. By selectively binding to cardiolipin in the inner mitochondrial membrane, this synthetic tetrapeptide stabilizes mitochondrial structure, reduces oxidative stress, enhances ATP production, and prevents the cascade of cellular damage that results from mitochondrial dysfunction [1].

The FDA approval of Elamipretide for Barth syndrome in September 2025 validated years of preclinical and clinical research and established a precedent for therapies targeting mitochondrial dysfunction [4]. The compelling results from the TAZPOWER trial, demonstrating sustained improvements in skeletal muscle strength and cardiac function over 168 weeks, provide strong evidence for the therapeutic potential of cardiolipin stabilization [1].

Perhaps most exciting are the research findings demonstrating that SS-31 can reverse age-related mitochondrial dysfunction and improve exercise tolerance by enhancing mitochondrial quality rather than quantity [2]. This paradigm-shifting discovery suggests that optimizing the function of existing mitochondria may be more effective than strategies focused solely on increasing mitochondrial content. Given the central role of mitochondrial dysfunction in aging and age-related diseases, these findings have profound implications for extending healthspan and improving quality of life in elderly populations.

While challenges remain in optimizing delivery, understanding long-term effects, and expanding applications to diverse mitochondrial-related conditions, the evidence to date supports the safety and efficacy of Elamipretide. Ongoing clinical trials in primary mitochondrial myopathy, age-related macular degeneration, and other conditions will further define the therapeutic potential of this innovative compound [1].

Future research may expand upon preclinical findings to develop clinical trials for neurodegenerative diseases, metabolic disorders, and other conditions where mitochondrial dysfunction is a core pathology. As our understanding of mitochondrial biology deepens and clinical experience with Elamipretide grows, this mitochondria-targeting peptide may emerge as a cornerstone therapy for a wide range of previously intractable diseases rooted in cellular energy failure.

References

1. Tung C, Varzideh F, Farroni E, Mone P, Kansakar U, Jankauskas SS, Santulli G. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025;26(3):944. Available from: https://www.mdpi.com/1422-0067/26/3/944

2. Campbell MD, Duan J, Samuelson AT, Gaffrey MJ, Merrihew GE, Egertson JD, Wang L, Bammler TK, Moore RJ, White CC, Kavanagh TJ, Voss JG, Szeto HH, Rabinovitch PS, MacCoss MJ, Qian WJ, Marcinek DJ. Improving mitochondrial function with SS-31 reverses age-related redox stress and improves exercise tolerance in aged mice. Free Radic Biol Med. 2019;134:268-281. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6588449/

3. Chavez JD, Tang X, Campbell MD, Reyes G, Kramer PA, Stuppard R, Keller A, Zhang L, Rabinovitch PS, Marcinek DJ, Bruce JE. Mitochondrial protein interaction landscape of SS-31. Proc Natl Acad Sci USA. 2020;117(26):15363-15373. Available from: https://www.pnas.org/doi/10.1073/pnas.2002250117

4. Johns Hopkins University. FDA approves drug for treatment of rare mitochondrial disorder. Johns Hopkins Hub. 2025 Sep 25. Available from: https://hub.jhu.edu/2025/09/25/fda-approves-barth-syndrome-treatment/

5. Zhu Y, Luo M, Bai X, Li J, Nie P, Li B, Xie W, Liu D, Yu P, Wang Y. SS-31, a Mitochondria-Targeting Peptide, Ameliorates Kidney Disease. Oxid Med Cell Longev. 2022;2022:1295509. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9192202/

---

Disclaimer: This article is for educational and research purposes only. It is not intended to provide medical advice, diagnosis, or treatment. SS-31 (Elamipretide) is a research peptide approved by the FDA only for the treatment of Barth syndrome. It is not approved for other conditions and should only be used under the supervision of qualified healthcare professionals in approved clinical settings. Research peptides discussed in this article are for laboratory and research use only and are not intended for human consumption outside of approved clinical trials. Always consult with qualified healthcare professionals before making any decisions related to your health or treatment options.